VEGF gene alternative splicing: pro- and anti-angiogenic isoforms in cancer

The anti-angiogenic isoforms of VEGF in health and disease

(2009) Yan Qiu et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Therapeutic potential of manipulating VEGF splice isoforms in oncology

(2009) Emma S Rennel et al.   Future Oncology

VEGF165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy

(2008) A H R Varey et al.   BRITISH JOURNAL OF CANCER

The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice

(2008) E S Rennel et al.   BRITISH JOURNAL OF CANCER

Vascular Endothelial Growth Factor (VEGF)-A165b Is a Weak In vitro Agonist for VEGF Receptor-2 Due to Lack of Coreceptor Binding and Deficient Regulation of Kinase Activity

(2008) H. Kawamura et al.   CANCER RESEARCH

Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors

(2008) D. G. Nowak et al.   JOURNAL OF CELL SCIENCE

Tumor Angiogenesis

(2008) Robert S. Kerbel   NEW ENGLAND JOURNAL OF MEDICINE

Vascular endothelial growth factor in eye disease

(2008) J.S. Penn et al.   PROGRESS IN RETINAL AND EYE RESEARCH

Mammary alveolar development during lactation is inhibited by the endogenous antiangiogenic growth factor isoform, VEGF165b

(2007) Yan Qiu et al.   FASEB JOURNAL